What is the diagnosis of a tumor that is positive for synaptophysin, Thyroid Transcription Factor-1 (TTF-1), cytokeratin (e.g. AE1/AE3, also known as Oscar cytokeratin is not a standard term, but assuming it refers to a type of cytokeratin), and has a high proliferation index, as indicated by a Ki-67 index of approximately 70%?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Differential Diagnosis

The provided information suggests a tumor with neuroendocrine and epithelial differentiation, high proliferative rate, and specific immunohistochemical markers. Here's a categorized differential diagnosis:

  • Single most likely diagnosis

    • Small cell lung carcinoma (SCLC): This diagnosis is most likely due to the tumor's positivity for TTF-1 (a marker often expressed in lung cancers), synaptophysin (indicating neuroendocrine differentiation), and a high Ki-67 index (suggesting a high proliferative rate, characteristic of SCLC). Oscar cytokeratin positivity also supports an epithelial origin, consistent with SCLC.
  • Other Likely diagnoses

    • Large cell neuroendocrine carcinoma (LCNEC) of the lung: Although less likely than SCLC due to the very high Ki-67 index, LCNEC could be considered, especially if the tumor shows large cell morphology and neuroendocrine markers. However, the Ki-67 index is typically lower in LCNEC compared to SCLC.
    • Merkel cell carcinoma: This is a rare skin tumor with neuroendocrine features, but it is less likely given the TTF-1 positivity, which strongly suggests a lung origin.
  • Do Not Miss

    • Other high-grade neuroendocrine carcinomas (e.g., from the gastrointestinal tract or thymus): Although less common, these tumors could present similarly and have a significant impact on treatment and prognosis. Missing these diagnoses could lead to inappropriate treatment.
    • Metastatic disease: Given the high Ki-67 index and specific markers, considering metastasis from another site (e.g., a high-grade neuroendocrine tumor from a different primary site) is crucial, especially if there's no clear lung primary.
  • Rare diagnoses

    • Primitive neuroectodermal tumor (PNET) or Ewing sarcoma with neuroendocrine differentiation: These tumors are rare and typically occur in younger individuals. They might express neuroendocrine markers and have a high proliferative index but are less likely given the specific marker profile (e.g., TTF-1 positivity).
    • NUT carcinoma: A rare, aggressive tumor characterized by NUT1 gene rearrangements, which might express cytokeratins and have a high Ki-67 index. However, the specific neuroendocrine markers and TTF-1 positivity make this less likely.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.